COCH Stock Forecast & Price Target

Envoy Medical is supported by a differentiated fully implanted hearing platform that could expand adoption by removing the stigma and inconvenience of external components, while its FDA-approved Esteem FI-AMEI provides an existing revenue base from implant and replacement sales. The July 2026 Stage 1 data strengthened the case for Acclaim, with mean CNC word recognition improving to 53.2% from 39.2% at six months and 15.2% pre-implant, nine of 10 participants showing a positive response, and no protocol-defined serious adverse events reported. Although 2Q26 revenue was only $51K and the net loss was $7.3M, the first PMA module was submitted in June 2026 and the 56-patient pivotal trial is advancing toward 2Q27 topline data, supporting a favorable long-term outlook.

Envoy Medical is facing a fragile financial position, with only $19.7M in cash at the end of June 2026 and $(5.5M) in operating cash outflows during 2Q26, which suggests limited runway without new funding. Although the Series A-1 and Series A-2 warrants could generate up to $48M of gross proceeds, the company may still need to raise additional capital within the next 12 months and could suffer dilution, especially given the November 16, 2026 NASDAQ bid-price compliance deadline. Fundamentally, the outlook is pressured by heavy dependence on the Esteem FI-AMEI, an unproven Acclaim CI that carries only a 55% U.S. approval probability, and ongoing losses tied to offering costs and warrant liability fair-value changes.